Axion’s MEA systems can model complex brain activity and heartbeats in a dish. As a result, toxicity and efficacy can be assessed earlier in the drug development process, and with greater sensitivity and accuracy. These comprehensive system-level evaluations provide an in vitro solution to reducing animal testing, a key objective of the Tox21 and REACH initiatives.
Axion’s MEA systems provide a label-free in vitro platform for direct measurement of electrical activity in neurons and cardiomyocytes, while the efficiency and convenience of Axion’s standard MEA plates facilitate use for screening-level applications. The large number of electrodes per well reveals detailed information about systems-level signal propogation.
Axion Maestro MEA system helps advance understanding of Parkinson’s disease
In groundbreaking research published in the journal Cell Reports, scientists at the New York Stem Cell Foundation Research Institute have created an in vitro “disease-in-a-dish” model of idiopathic Parkinson’s Disease (PD) using dopaminergic neurons derived from human induced pluripotent stem cells. Comparison of neurons derived from affected and unaffected identical twins has allowed important cellular disease mechanisms to be observed for the first time in the lab. Axion’s Maestro MEA system was instrumental in characterizing electrical deficits in neurons derived from the twin with PD.
View the Press Release
New Maestro assay demonstrates highly accurate prediction of drug-induced seizure liability
Atlanta, GA – October 31, 2014 – At the recent Safety Pharma Society (SPS) conference, GSK safety scientist, Dr. Khuram Chaudhary, demonstrated high sensitivity and specificity for seizure prediction using six proprietary compounds. This new cell-based seizure prediction assay demonstrates improved predictivity and throughput over traditional brain-slice assays.